恒瑞医药SHR7280片药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application SHR7280 from the National Medical Products Administration, indicating progress in its development for assisted reproductive technology [1] Group 1: Drug Information - SHR7280 is an oral small molecule GnRH receptor antagonist designed to prevent early luteinizing hormone (LH) peaks in patients undergoing controlled ovarian stimulation [1] - The drug works by blocking the binding of endogenous GnRH to GnRH receptors, thereby inhibiting the synthesis and release of LH and other gonadotropins [1] Group 2: Application and Indication - The intended use of SHR7280 is in controlled ovarian hyperstimulation treatment within assisted reproductive technology [1]